Monitoring central nervous system tumour metabolism using cerebrospinal fluid

Area of Science:

• Neuro-oncology
• Biomarker discovery
• Clinical chemistry

Background:

• Central nervous system (CNS) tumours are a leading cause of cancer death in young adults in the UK.
• Persistent, recurrent, and metastatic CNS tumours necessitate effective longitudinal monitoring strategies.
• Current monitoring methods require improvement in specificity, sensitivity, speed, cost, and patient acceptance.

Purpose of the Study:

• To review the potential of cerebrospinal fluid (CSF) metabolites as biomarkers for CNS tumours.
• To evaluate CSF metabolite biomarkers for monitoring tumour remission, progression, drug response, recurrence, and metastasis.
• To discuss the clinical benefits and risks associated with using CSF metabolite biomarkers.

Main Methods:

• Literature review focusing on the utility of CSF metabolites in CNS tumour management.
• Analysis of existing research on biomarker potential in cerebrospinal fluid.
• Discussion of clinical implications and future research directions.

Main Results:

• Cerebrospinal fluid (CSF) examination, particularly with enhanced metabolite biomarkers, holds significant potential for CNS tumour monitoring.
• Metabolites in CSF could serve as specific and sensitive indicators of tumour status, including remission, progression, and recurrence.
• This approach may offer advantages over existing diagnostic tests, leveraging existing hospital instrumentation.

Conclusions:

• CSF metabolite biomarkers present a promising avenue for improving the management of CNS tumours.
• Further research investment is crucial to identify novel biomarkers, elucidate their tumour-specific relationships, and validate them through standardized assays.
• Standardized and validated CSF metabolite biomarker assays are needed to transition this approach into clinical practice.